Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentric Multinational Observational Study to Describe the Shift in Stage at Diagnosis of Lung Cancer. No Direct Recruitment of Patients or Administration of Study Medication.

NCT06842056 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06842056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06842056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentric Multinational Observational Study to Describe the Shift in Stage at Diagnosis of Lung Cancer. No Direct Recruitment of Patients or Administration of Study Medication.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Not yet recruiting
Start date
April 1, 2027
Completion date
March 31, 2030
Enrollment
3,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer